X4 Pharmaceuticals, Inc
Total Trades
73
Buys
3
Sells
59
Largest Trade
N/A
Insiders
11
Institutional Funds
56
Inst. Value
$1M+
Activist Filings
49
Insider Trades
| Insider | Title | Type | Value | Shares | Price | Date |
|---|---|---|---|---|---|---|
| Craig Adam R | Executive Chairman | BUY | $100K–$500K | 86K | $2.90 | Oct 27, 2025 |
| Baldry Mark | Chief Commercial O… | BUY | $1K–$15K | 1K | $2.48 | May 20, 2025 |
| Ragan Paula | President and CEO | GRANT | N/A | 170K | — | Jan 27, 2025 |
| Ragan Paula | President and CEO | SELL | $15K–$50K | 76K | $0.45 | Jan 27, 2025 |
| Mostafa Adam S. | CFO | GRANT | N/A | 75K | — | Jan 27, 2025 |
| Mostafa Adam S. | CFO | SELL | $15K–$50K | 75K | $0.45 | Jan 27, 2025 |
| Baldry Mark | Chief Commercial O… | SELL | $1K–$15K | 29K | $0.45 | Jan 27, 2025 |
| Baldry Mark | Chief Commercial O… | GRANT | N/A | 75K | — | Jan 27, 2025 |
| DiBiase Mary | COO | GRANT | N/A | 61K | — | Jan 27, 2025 |
| DiBiase Mary | COO | SELL | $1K–$15K | 22K | $0.45 | Jan 27, 2025 |
| Arbet-Engels Christophe | Chief Medical Offi… | GRANT | N/A | 26K | — | Jan 27, 2025 |
| Arbet-Engels Christophe | Chief Medical Offi… | SELL | $1K–$15K | 12K | $0.45 | Jan 27, 2025 |
| Ragan Paula | President and CEO | SELL | $1K–$15K | 32K | $0.39 | Nov 19, 2024 |
| Ragan Paula | President and CEO | SELL | $15K–$50K | 32K | $0.56 | Oct 16, 2024 |
| Mostafa Adam S. | CFO | GRANT | N/A | 231K | — | Oct 8, 2024 |
| Mostafa Adam S. | CFO | SELL | $100K–$500K | 231K | $0.55 | Oct 8, 2024 |
| Baldry Mark | Chief Commercial O… | SELL | $1K–$15K | 11K | $0.58 | Oct 8, 2024 |
| Baldry Mark | Chief Commercial O… | GRANT | N/A | 35K | — | Oct 8, 2024 |
| Ragan Paula | President and CEO | GRANT | N/A | 532K | — | Oct 8, 2024 |
| Ragan Paula | President and CEO | SELL | $100K–$500K | 239K | $0.55 | Oct 8, 2024 |
| DiBiase Mary | COO | GRANT | N/A | 231K | — | Oct 8, 2024 |
| DiBiase Mary | COO | SELL | $15K–$50K | 68K | $0.57 | Oct 8, 2024 |
| Taveras Arthur | Chief Scientific O… | SELL | $15K–$50K | 77K | $0.56 | Oct 8, 2024 |
| Taveras Arthur | Chief Scientific O… | GRANT | N/A | 231K | — | Oct 8, 2024 |
| DiBiase Mary | COO | SELL | $1K–$15K | 4K | $1.01 | Feb 12, 2024 |
| Taveras Arthur | Chief Scientific O… | SELL | <$1K | 787 | $1.01 | Feb 12, 2024 |
| Ragan Paula | President and CEO | SELL | $15K–$50K | 22K | $1.01 | Feb 12, 2024 |
| Mostafa Adam S. | CFO | SELL | $15K–$50K | 28K | $1.01 | Feb 12, 2024 |
| Ragan Paula | President and CEO | SELL | $100K–$500K | 239K | $0.76 | Nov 3, 2023 |
| Mostafa Adam S. | CFO | SELL | $100K–$500K | 231K | $0.73 | Nov 3, 2023 |
| DiBiase Mary | COO | SELL | $15K–$50K | 68K | $0.73 | Nov 3, 2023 |
| Baldry Mark | Chief Commercial O… | SELL | $1K–$15K | 10K | $0.73 | Nov 3, 2023 |
| Taveras Arthur | Chief Scientific O… | SELL | $15K–$50K | 68K | $0.73 | Nov 3, 2023 |
| DiBiase Mary | COO | SELL | $1K–$15K | 3K | $1.25 | Sep 12, 2023 |
| WYZGA MICHAEL S | Director | BUY | $15K–$50K | 25K | $1.20 | Aug 22, 2023 |
| Stewart Murray | Interim Chief Medi… | GRANT | N/A | 270K | — | Aug 11, 2023 |
| Stewart Murray | Interim Chief Medi… | SELL | $100K–$500K | 130K | $1.06 | Aug 11, 2023 |
| DiBiase Mary | COO | SELL | <$1K | 464 | $1.89 | Jul 5, 2023 |
| Mostafa Adam S. | CFO | SELL | $1K–$15K | 3K | $1.89 | Jul 5, 2023 |
| DiBiase Mary | COO | SELL | $1K–$15K | 857 | $1.93 | Jun 26, 2023 |
| Mostafa Adam S. | CFO | SELL | $1K–$15K | 5K | $1.93 | Jun 26, 2023 |
| Ragan Paula | President and CEO | SELL | $1K–$15K | 7K | $1.92 | Jun 26, 2023 |
| DiBiase Mary | COO | SELL | $1K–$15K | 857 | $2.23 | Jun 16, 2023 |
| Mostafa Adam S. | CFO | SELL | $1K–$15K | 5K | $2.22 | Jun 16, 2023 |
| Ragan Paula | President and CEO | SELL | $1K–$15K | 7K | $2.23 | Jun 16, 2023 |
| Ragan Paula | President and CEO | SELL | $1K–$15K | 6K | $1.95 | May 31, 2023 |
| DiBiase Mary | COO | SELL | $15K–$50K | 18K | $0.84 | Mar 13, 2023 |
| Mostafa Adam S. | CFO | SELL | $15K–$50K | 53K | $0.84 | Mar 13, 2023 |
| Taveras Arthur | Chief Scientific O… | SELL | $1K–$15K | 17K | $0.84 | Mar 13, 2023 |
| Ragan Paula | President and CEO | SELL | $15K–$50K | 50K | $0.84 | Mar 13, 2023 |
Institutional Ownership
13F filings as of Dec 31, 2025 · 56 funds holding
| Fund | Shares | Value | Type |
|---|---|---|---|
| Empery Asset Management, LP | 9.0M | $1M+ | SH |
| MORGAN STANLEY | 8.2M | $1M+ | SH |
| Bain Capital Life Sciences Investors, LLC | 8.0M | $1M+ | SH |
| PERCEPTIVE ADVISORS LLC | 6.3M | $1M+ | SH |
| Deep Track Capital, LP | 5.0M | $1M+ | SH |
| Kalehua Capital Management LLC | 3.7M | $1M+ | SH |
| BRAIDWELL LP | 3.4M | $1M+ | SH |
| NEA Management Company, LLC | 3.2M | $1M+ | SH |
| VANGUARD GROUP INC | 2.9M | $1M+ | SH |
| Rosalind Advisors, Inc. | 2.6M | $1M+ | SH |
| Trails Edge Capital Partners, LP | 2.6M | $1M+ | SH |
| Nantahala Capital Management, LLC | 2.4M | $1M+ | SH |
| Samsara BioCapital, LLC | 2.0M | $1M+ | SH |
| Siren, L.L.C. | 1.5M | $1M+ | SH |
| GOLDMAN SACHS GROUP INC | 832K | $1M+ | SH |
| Point72 Asset Management, L.P. | 808K | $1M+ | SH |
| GEODE CAPITAL MANAGEMENT, LLC | 797K | $1M+ | SH |
| Stonepine Capital Management, LLC | 594K | $1M+ | SH |
| SILVERARC CAPITAL MANAGEMENT, LLC | 357K | $1M+ | SH |
| STATE STREET CORP | 198K | $500K+ | SH |
Activist & 5%+ Owners
SC 13D/13G filings — investors holding 5%+ of outstanding shares
SC 13G/A · Mar 6, 2026
10.2%
8.9M shares
Saturn V Capital Management LP
SC 13G · Feb 17, 2026
7.4%
6.4M shares
Nantahala Capital Management, LLC
SC 13G/A · Feb 13, 2026
2.8%
2.4M shares
SC 13G · Feb 12, 2026
9.4%
8.2M shares
SC 13G/A · Feb 5, 2026
9.7%
8.5M shares
SC 13G/A · Jan 15, 2026
10.0%
9.0M shares
Nantahala Capital Management, LLC
SC 13G · Nov 14, 2025
10.0%
2.2M shares
SC 13G · Nov 7, 2025
14.8%
8.5M shares
SC 13G · Nov 3, 2025
7.6%
6.1M shares
Growth Equity Opportunities 18 VGE, LLC
SC 13D/A · Oct 29, 2025
6.2%
5.1M shares
SC 13G · Oct 21, 2025
10.0%
2.5M shares
SC 13G · Oct 3, 2025
10.0%
2.5M shares
Bain Capital Life Sciences Fund, L.P.
SC 13G · Sep 15, 2025
10.0%
2.4M shares
SC 13G · Aug 20, 2025
5.2%
1.2M shares
SC 13G · Aug 19, 2025
10.0%
2.4M shares
Trails Edge Capital Partners, LP
SC 13G · Aug 18, 2025
9.9%
2.3M shares
SC 13D · Aug 18, 2025
10.0%
2.5M shares
Growth Equity Opportunities 18 VGE, LLC
SC 13D/A · Aug 15, 2025
10.0%
2.2M shares
SC 13G/A · Aug 14, 2025
1.7%
135K shares
Bain Capital Life Sciences Fund, L.P.
SC 13D · Aug 14, 2025
10.0%
2.4M shares
SC 13G/A · Jul 18, 2025
3.0%
179K shares
SC 13G/A · Jan 31, 2025
4.8%
8.2M shares
SC 13G/A · Nov 12, 2024
5.0%
8.4M shares
SC 13G · Nov 8, 2024
6.7%
11.2M shares
SC 13G/A · Nov 4, 2024
5.0%
8.4M shares
SC 13G · Oct 22, 2024
6.7%
11.2M shares
SC 13G/A · Feb 15, 2024
6.7%
11.5M shares
SC 13G · Feb 14, 2024
4.8%
8.2M shares
Lincoln Park Capital Fund, LLC
SC 13G/A · Feb 14, 2024
0.9%
1.6M shares
Bain Capital Life Sciences Fund, L.P. 2
SC 13G/A · Feb 13, 2024
10.0%
16.9M shares
SC 13G · Jan 31, 2024
5.0%
8.4M shares
SC 13G/A · Jan 16, 2024
1.0%
1.7M shares
SC 13G/A · Jan 8, 2024
2.6%
4.5M shares
SC 13G · Jun 16, 2023
5.2%
8.3M shares
Growth Equity Opportunities 18 VGE, LLC
SC 13D/A · May 26, 2023
10.0%
15.7M shares
SC 13G/A · Feb 14, 2023
8.2%
10.3M shares
SC 13G/A · Feb 14, 2023
0.3%
349K shares
Bain Capital Life Sciences Fund, L.P.
SC 13G/A · Feb 14, 2023
10.0%
12.2M shares
Biotechnology Value Fund, L.P.
SC 13G/A · Feb 13, 2023
1.0%
1.2M shares
SC 13G · Jan 13, 2023
5.1%
6.2M shares
Growth Equity Opportunities 18 VGE, LLC
SC 13D/A · Dec 19, 2022
10.0%
12.1M shares
Growth Equity Opportunities 18 VGE, LLC
SC 13D · Jul 19, 2022
9.9%
6.9M shares
SC 13G/A · Feb 14, 2022
8.1%
2.3M shares
SC 13G/A · Feb 14, 2022
3.9%
1.1M shares
Biotechnology Value Fund, L.P.
SC 13G/A · Feb 14, 2022
5.8%
1.7M shares
Bain Capital Life Sciences Fund, L.P.
SC 13G/A · Feb 14, 2022
10.0%
2.9M shares
SC 13G/A · Feb 11, 2022
6.4%
1.8M shares
SC 13G/A · Feb 11, 2022
6.1%
1.5M shares
Lincoln Park Capital Fund, LLC
SC 13G · Jan 19, 2022
6.4%
1.8M shares